Trazodonum [Latin] en es it fr

Trazodonum [Latin] Brand names, Trazodonum [Latin] Analogs

Trazodonum [Latin] Brand Names Mixture

  • No information avaliable

Trazodonum [Latin] Chemical_Formula


Trazodonum [Latin] RX_link

Trazodonum [Latin] fda sheet

Trazodonum_[Latin] FDA

Trazodonum [Latin] msds (material safety sheet)

Trazodonum [Latin] Synthesis Reference

Palazzo, Silvestrini, U.S. Pat 3,381,009 (1968)

Trazodonum [Latin] Molecular Weight

371.864 g/mol

Trazodonum [Latin] Melting Point

86-87 oC

Trazodonum [Latin] H2O Solubility

Sparigly soluble

Trazodonum [Latin] State


Trazodonum [Latin] LogP


Trazodonum [Latin] Dosage Forms


Trazodonum [Latin] Indication

For the treatment of depression.

Trazodonum [Latin] Pharmacology

Trazodone is an antidepressant and hypnotic chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. The mechanism of trazodone's antidepressant action in man is not fully understood. In animals, trazodone selectively inhibits serotonin uptake by brain synaptosomes and potentiates the behavioral changes induced by the serotonin precursor, 5-hydroxytryptophan. Cardiac conduction effects of trazodone in the anesthetized dog are qualitatively dissimilar and quantitatively less pronounced than those seen with tricyclic antidepressants. Trazodone is not a monoamine oxidase inhibitor and, unlike amphetamine-type drugs, does not stimulate the central nervous system. In man, trazodone is well absorbed after oral administration without selective localization in any tissue. Since the clearance of trazodone from the body is sufficiently variable, in some patients trazodone may accumulate in the plasma.

Trazodonum [Latin] Absorption

Well absorbed following oral administration.

Trazodonum [Latin] side effects and Toxicity

LD50=96mg/kg (i.v. in mice)

Trazodonum [Latin] Patient Information

Trazodonum [Latin] Organisms Affected

Humans and other mammals